Commitments and Contingencies - Additional Information (Detail)	0 Months Ended	3 Months Ended	9 Months Ended			3 Months Ended	9 Months Ended	3 Months Ended
	Jun. 30, 2013 USD ($)	Sep. 30, 2013 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2014 EUR (€)	Jun. 30, 2014 Patents [Member]	Jun. 30, 2014 SRI Litigation [Member] USD ($)	Jun. 30, 2014 SRI Litigation [Member] USD ($)	Sep. 30, 2013 Prior to Fiscal 2013 [Member] USD ($)
Commitments and Contingencies [Line Items]
Additional litigation expense within discontinued operations						$ 100,000	$ 100,000
Unreimbursed legal expenses	1,300,000
Payment received on unreimbursed legal expenses		1,000,000
Legal expenses								600,000
Additional shares of common stock to stockholders			480,059	480,059
License agreement commencement date			2006-03	2006-03
Annual minimum payments for licenses			273,000	200,000
Exchange rate relating to license payment			$ 1.36452
Future minimum payments associated with license			3,600,000
Patent expiry date					2027-09
Additional maximum amount payable on successful achievement of specified milestones to sellers of PR Pharma			2,500,000
Indemnification period			5 years	5 years
Accrual for contingency			$ 0